Best for type 2 diabetes
The best GLP‑1 medications for type 2 diabetes in 2026
Chronic condition involving insulin resistance and elevated blood glucose.
Find the right type 2 diabetes treatment in 30 seconds
Quick decision tree — answer 2–4 questions, get a personalized recommendation. No email required.
Is your A1C above 7.5%?
Most relevant drugs
Top-scored options for type 2 diabetes
Each score is our overall rating from the clinical rubric (effectiveness, safety, evidence, value). The left rule is color-keyed to the molecule.
8.9
/ 10
Form Health
Brand-name GLP-1 (Wegovy, Zepbound, etc.)
Read the full review →
8.7
/ 10
Mounjaro
Tirzepatide
Read the full review →
8.5
/ 10
Ozempic
Semaglutide
Read the full review →
8.0
/ 10
Rybelsus
Semaglutide (oral, 14mg max for T2D)
Read the full review →
Molecule key: Semaglutide Tirzepatide Oral Other GLP-1
Full ranking
Every GLP-1 we rank for type 2 diabetes
- Top pick1
Obesity-medicine telehealth that takes insurance
- Insurance-accepting (rare for GLP-1 telehealth)
- Board-certified obesity medicine physicians
- Brand-name only — no compounding gamble
FDA-approvedBrand-nameOnce-weekly injectionInsurance eligibleSee review8.9/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there. - 2Runner-up
Tirzepatide for type 2 diabetes
- Significant A1C reduction
- Substantial weight loss as side benefit
Off-label useOnce-weekly injectionDual GIP / GLP-1Insurance eligible8.7/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there.See reviewTrue cost · maint.$549/mo · 7.5mg+$150 - 3Also great
Semaglutide approved for type 2 diabetes
- Strong A1C reduction in T2D
- Often covered by insurance for diabetes indication
Off-label useOnce-weekly injectionGLP-1 receptor agonistInsurance eligible8.5/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there.See reviewTrue cost · maint.$499/mo · 1mg - 4
Oral semaglutide for type 2 diabetes (FDA-approved 2019)
- First FDA-approved oral GLP-1 (2019) — long real-world safety record
- T2D indication = strong insurance coverage
- No injection
FDA-approvedBrand-nameDaily oral tabletGLP-1 receptor agonistInsurance eligibleSee review8.0/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there. - 5
Primary care telehealth with GLP-1 prescribing
- Includes primary care visits
- Insurance accepted
FDA-approvedBrand-nameOnce-weekly injectionSee review7.6/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there.
Quick comparison
Verified Jul 17, 2026| # | Product | Active ingredient | Starting price | True cost · maint. | FDA status | Score | |
|---|---|---|---|---|---|---|---|
| 1 | Form Health | Brand-name GLP-1 (Wegovy, Zepbound, etc.) | Best ·$99/mo | approved | Top ·8.9 | View → | |
| 2 | Mounjaro | Tirzepatide | $1349/mo | $549/mo · 7.5mg+$150 | off-label | 8.7 | View → |
| 3 | Ozempic | Semaglutide | $997/mo | Best ·$499/mo · 1mg | off-label | 8.5 | View → |
| 4 | Rybelsus | Semaglutide (oral, 14mg max for T2D) | $997/mo | approved | 8.0 | View → | |
| 5 | PlushCare Weight Loss | Brand-name GLP-1 | Best ·$99/mo | approved | 7.6 | View → |
Summary
Our recommendations for type 2 diabetes
A short read of who wins for which kind of patient.
Recommendation labels are computed from each product’s editorial badges + scoring rubric. See methodology for the full rubric — page /best-glp1-for/type-2-diabetes.
Evidence
What the trials show
In the head-to-head SURPASS-2 trial (n=1879, T2D inadequately controlled on metformin), tirzepatide lowered HbA1c by 2.01–2.30% across doses vs 1.86% for semaglutide 1 mg, with tirzepatide superior at all doses. SUSTAIN-6 (n=3297, T2D with high cardiovascular risk) showed semaglutide reduced major adverse cardiovascular events by 26% (HR 0.74, 95% CI 0.58–0.95), establishing the class cardiovascular-benefit label. Oral semaglutide (PIONEER-6, n=3183) demonstrated non-inferior cardiovascular safety (HR 0.79, 95% CI 0.57–1.11). These agents also reduce body weight, but their T2D approvals rest on glycemic and, for some, cardiovascular and kidney outcomes.
Prescribing
How prescribers handle it
For T2D, prescribing is on-label and straightforward — no obesity BMI threshold is required. ADA guidance favors GLP-1 (or GLP-1/GIP) agents in patients where weight management or established ASCVD/CKD is a priority. Ozempic, Mounjaro, Rybelsus, and Trulicity are the diabetes-indicated brands; do not prescribe Wegovy or Zepbound for a diabetes-only indication, as those are the obesity-indicated brands of semaglutide and tirzepatide respectively.
Insurance
How coverage works
A T2D diagnosis is the single cleanest prior-authorization pathway in the category — far easier than any weight-loss or off-label route. Most commercial plans, Medicare Part D, and Medicaid cover the diabetes-indicated brands (Ozempic, Mounjaro, Rybelsus, Trulicity) for documented T2D. Step therapy (metformin first) is common; an A1C and metformin trial in the chart typically clears the PA.
Cautions
Contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2 (boxed warning, class-wide). Use caution with insulin or sulfonylureas due to hypoglycemia risk — those doses often need reduction. Pancreatitis, gallbladder disease, and dose-dependent GI effects (nausea, vomiting, diarrhea) are the common adverse events. Not a substitute for insulin in type 1 diabetes or diabetic ketoacidosis.
Editorial verdict
What we recommend
For type 2 diabetes, GLP-1 and dual GIP/GLP-1 agents are now a mainstay rather than a niche — on-label, well-evidenced for both glycemic control and (for semaglutide and tirzepatide molecules) cardiovascular and kidney outcomes. The diabetes brands also carry the easiest insurance path. If weight is a co-priority, the same molecule under its obesity brand is what gets prescribed off the diabetes pathway — but for a diabetes diagnosis, stay on the diabetes-indicated brand.
Frequently asked questions
Which GLP-1 is best for type 2 diabetes?+
Our #1 pick is Form Health. It scored highest on effectiveness and safety for type 2 diabetes based on our clinical rubric.
What does the evidence show for GLP-1 medications and type 2 diabetes?+
In the head-to-head SURPASS-2 trial (n=1879, T2D inadequately controlled on metformin), tirzepatide lowered HbA1c by 2.01–2.30% across doses vs 1.86% for semaglutide 1 mg, with tirzepatide superior at all doses. SUSTAIN-6 (n=3297, T2D with high cardiovascular risk) showed semaglutide reduced major adverse cardiovascular events by 26% (HR 0.74, 95% CI 0.58–0.95), establishing the class cardiovascular-benefit label. Oral semaglutide (PIONEER-6, n=3183) demonstrated non-inferior cardiovascular safety (HR 0.79, 95% CI 0.57–1.11). These agents also reduce body weight, but their T2D approvals rest on glycemic and, for some, cardiovascular and kidney outcomes.
Does insurance cover GLP-1 medications for type 2 diabetes?+
A T2D diagnosis is the single cleanest prior-authorization pathway in the category — far easier than any weight-loss or off-label route. Most commercial plans, Medicare Part D, and Medicaid cover the diabetes-indicated brands (Ozempic, Mounjaro, Rybelsus, Trulicity) for documented T2D. Step therapy (metformin first) is common; an A1C and metformin trial in the chart typically clears the PA.
Are GLP-1 medications safe for type 2 diabetes?+
Contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2 (boxed warning, class-wide). Use caution with insulin or sulfonylureas due to hypoglycemia risk — those doses often need reduction. Pancreatitis, gallbladder disease, and dose-dependent GI effects (nausea, vomiting, diarrhea) are the common adverse events. Not a substitute for insulin in type 1 diabetes or diabetic ketoacidosis.
The bottom line
Best GLP-1 for type 2 diabetes
For type 2 diabetes, GLP-1 and dual GIP/GLP-1 agents are now a mainstay rather than a niche — on-label, well-evidenced for both glycemic control and (for semaglutide and tirzepatide molecules) cardiovascular and kidney outcomes. The diabetes brands also carry the easiest insurance path. If weight is a co-priority, the same molecule under its obesity brand is what gets prescribed off the diabetes pathway — but for a diabetes diagnosis, stay on the diabetes-indicated brand.